High-density lipoprotein profile in newly-diagnosed lower extremity artery disease in Slovak population without diabetes mellitus

Neuroendocrinology Letters

Volumn 35, Issue 6, 2014, Pages 531-535

  Kasko, Martin ^a   Gaspar, Ludovit ^a   Dukat, Andrej ^a   Gavornik, Peter ^a   Oravec, Stanislav ^a  

^a Bratislava   (Slovakia)

Author keywords

Atherosclerosis; HDL; Lipoproteins; PAD

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; POLYACRYLAMIDE GEL;

ADULT; ANAMNESIS; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; LIPOPRINT LDL AND HDL SYSTEM; LOWER EXTREMITY ARTERY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PILOT STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; SLOVAK (CITIZEN); SLOVAKIA; AGED; ATHEROSCLEROSIS; BLOOD; CHEMISTRY; DIABETES MELLITUS; ELECTROPHORESIS; METABOLISM; PREDICTIVE VALUE; PROCEDURES;

AGED; ATHEROSCLEROSIS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ELECTROPHORESIS; FEMALE; HUMANS; LIPOPROTEINS, HDL2; LIPOPROTEINS, HDL3; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; SLOVAKIA;

EID: 84922534092     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Aboyans V, Mcdelland RL, Allison MA, Mcdermott MM, Blumenthal RS, Macura K, et al. (2011). Prevalence and risk factors of lower extremity artery disease in subjects without traditional modifiable cardiovascular risk factors. The multi-ethnic study of atherosclerosis. Archives of Cardiovascular Diseases Supplements. 3:72-78.
2. Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN (2002). Gradient gel electrophoretic separation of LDL and HDL subclasses on BioRad Mini Protean II and size phenotyping in healthy Macedonians. Clin Chim Acta. 317(1-2):119-123.
3. Albers JJ, Aladjem F (1971). Precipitation of 1251-labeled lipoproteins with specific polypeptide antisera: Evidence for two populations with differing polypeptide compositions in human high density lipoproteins. Biochemistry. 262:2405.
4. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, et al. (2004). High density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. ArteriosderThromb Vase Biol. 24(11):2181-2189.
5. Austin MA, King MC, Vranizan KM, Krauss RM (1990). Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 82(2):495-506.
6. Cooney MT, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A, et al. (2009). HDL cholesterol protects against cardiovascular disease in both genders, at all ages and all levels of risk. Atherosclerosis. 206:611-616.
7. Despres JP (2007). Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol. 6(2):51-59.
8. Dukát A (2008). Reziduálne kardiovaskulárne riziko - závažný problém, ktory si bude vyžadovat' nové liečebné prístupy (Residual cardiovascular risk - important problem which calls for a new treatment methods). Cardiol. 17(6):229-233.
9. Gašpar L, Makovník M, Hlinštáková S, Gavorník P, Dukát A, Štvrtinová V, et al. (2011). Médiokalcinóza - marker zvýšeného kardiovaskulárneho rizika (Mediocalcinosis - the marker of high cardiovascular risk). Vask Med. 3(1):29-31.
10. Gavorník P (2010). Obliterujúce choroby artérií a končatinovo-cievna ischemická choroba. Nová klinicko-etiologicko-anato-micko-patofyziologická (CEAP) klasifikácia (Arterial obliterative diseases and extremitovascular ischemic disease. New Clinica-l-Etiology-Anatomy-Pathophysiology (CEAP) classification.). Cardiology. 19(3):201-213.
11. Gavornik P, Dukat A, Gaspar L, Oravec S, Caprnda M, Vacula I, et al. (2010). Prevention and treatment of extremity vascular ischemic disease. Vnitr Lek. 56(6):613-9.
12. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. (1989). High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:8-15.
13. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977). High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 62:707-714.
14. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, et al. (2001). Development of a rapid quantitative method for LDL subfraction with use of the Quantimetrix Lipoprint LDL system. Clin Chem. 47(2):266-274.
15. Huang Y, Von Eckardstein A, Wu S, Assmann G (1995). Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-l and LpA-l/A-ll in native plasma. Arteriosder Thromb Vase Biol. 15:1412.
16. Kostner GM, Laggner P (1989). Chemical and physical properties of lipoproteins. In: Fruchart JC, Shepherd J editors. Clinical Biochemistry - Human Plasma Lipoproteins. Berlin, New York: Walter de Gruyter. p. 23-54.
17. Kralova Lesna I, Poledne R, Pagacova L, Stavek P, Pitha J (2012). HDL and apolipoprotein Al concentrations as markers of cholesterol efflux in middle-aged women: interaction with smoking. Neuroendocrinol Lett. 32 Suppl 2:38-42.
18. Morais J (2005a). Quantimetrix shows that all HDL subfractions may not protect against heart disease. ACC international congress of Clinical Chemistry. Orlando, FL.
19. Morais J, Muniz N (2005b). Differences in HDL subfraction distribution in normolipidemic versus dyslipidemic individuals. Presented at AACC, 57th Annual meeting. Orlando, FL.
20. ® HDL Method. Presented at AACC, 55th Annual meeting. Philadelphia, PA.
21. Okuda LS, Castilho G, Rocco DD, Nakandakare E, Catanozi S, Passarelli M (2011). HDL loses its anti-inflammatory property and even induces more inflammation in S100B or LPS stimulated macrophages previously exposed to AGE albumin. Atherosclerosis Supplements. 12(1):13-184.
22. Oravec S, Dostał E, Gruber K (2013). Lipoprotein Lp (a) in lipoprotein spectrum indentified by Lipoprint LDL system. Neuroendocrinol Lett. 34(4):309-13.
23. Oravec S, Dostał E, Dukat A, Gavornik P, Kucera M, Gruber K (2011a). HDL subfractions analysis: A new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipopro-teinemia. Neuroendocrinol Lett. 32(4):502-509.
24. Oravec S, Dukat A, Gavornik P, Lovasova Z, Gruber K (2011b). Atherogenic normolipidemia - a new phenomenon in the lipoprotein profile of clinically healthy subjects. Neuroendocrinol Lett. 32(3):317-321.
25. Oravec S, Gruber K, Dostał E, Miki J (2011c). Hyper-betalipopro-teinemia LDL 1, 2: A newly identified nonatherogenic hypercholesterolemia in a group of hypercholesterolemic subjects. Neuroendocrinol Lett. 32(3):322-327.
26. Oravec S, Krivosikova Z, Krivosik M, Gruber K, Gruber M, Dukat A, et al. (2011d). Lipoprotein profile in patients who survive a stroke. Neuroendocrinol Lett. 32(4):496-501.
27. Otvos JD, Jeyarajah EJ, Bennet SW, Krauss RM (1992). Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma protein concentrations and subspecies distribution from a single, rapid measurement. Clin Chem. 38(9):1632-1638.
28. Rainwater DL, Moore PH Jr, Shelledy WR, Dyer TD, Slifer SH (1997). Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. J Lipid Res. 38(6):1261-1266.
29. Tsuzaki K, Kotani K, Sano Y, Fujiwara S, Gazi IF, Elisaf M, et al. (2012). The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. Metabolism. 61(1):17-21.
30. Van J, Pan J, Charles MA, Krauss R, Wong N, Wu X (2007). Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med. 131(11):1679-1685.